BACKGROUND _ AIMS: Weight gain is an undesirable side effect of second-generation antipsychotics (SGAs). We performed this study to examine the influence of SGAs on resting energy expenditure (REE) and the relationship of REE to @entity1017 in adolescent patients. METHODS: Antipsychotic-na  ve or quasi-na  ve (<72 h of exposure to antipsychotics) adolescent @entity1 taking @entity1037 , @entity1089 , or @entity1090 in monotherapy were followed up for one year. We performed a prospective study (baseline, 1, 3, 6, and 12 months after treatment) based on anthropometric measurements, bioelectrical impedance analysis, and indirect calorimetry (Deltatrac    II MBM-200) to measure REE. We also analyzed metabolic and hormonal data and adiponectin concentrations. RESULTS: Forty-six out of the 54 @entity1 that started treatment attended at least 2 visits, and 16 completed 1 year of follow-up. @entity1 gained 10.8    6.2 kg (60% in the form of fat mass) and increased their waist circumference by 11.1    5.0 cm after 1 year of treatment. The REE/kg body mass ratio decreased (p = 0.027), and the REE/percentage @entity1386 ( @entity1386 ) ratio increased (p = 0.007) following the fall in the percentage of @entity1386 during treatment. Weight increase was significantly correlated with the REE/percentage @entity1386 ratio at all the visits (1-3-6-12 months) (r = 0.69, p = 0.004 at 12 months). CONCLUSIONS: SGAs seem to induce a hypometabolic state (reflected as decreased REE/kg body mass and increased REE/percentage @entity1386 ). This could explain, at least in part, the changes in weight and body composition observed in these @entity1 .

Influence of resting energy expenditure on XXXX in adolescents taking second-generation antipsychotics.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1386 :: ('MESH:D018205', 'Disease') :: ['fat-free mass', 'FFM'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine'] @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']
@entity1017 :: (MESH:D015430,Disease) :: ['weight gain']
